Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells.
Sen A
,
O'Malley K
,
Wang Z
,
Raj GV
,
Defranco DB
,
Hammes SR
.
???displayArticle.abstract???
Although transcriptional effects of androgens have been extensively studied, mechanisms regulating transcription-independent (nongenomic) androgen actions are poorly understood. Previously, we have shown that paxillin, a multidomain adaptor protein, is a critical regulator of testosterone-induced MAPK-signaling during Xenopus oocyte maturation. Here we examine the nongenomic effects of dihydrotestosterone (DHT) in prostate cancer cells, focusing on how paxillin mediates Erk signaling and downstream physiologic actions. We show that in LnCAP cells DHT functions as a growth factor that indirectly activates the EGF-receptor (EGFR) via androgen receptor binding and matrix metalloproteinase-mediated release of EGFR ligands. Interestingly, siRNA-mediated knockdown of paxillin expression in androgen-dependent LnCAP cells as well as in androgen-independent PC3 cells abrogates DHT- and/or EGF-induced Erk signaling. Furthermore, EGFR-induced Erk activation requires Src-mediated phosphorylation of paxillin on tyrosines 31/118. In contrast, paxillin is not required for PKC-induced Erk signaling. However, Erk-mediated phosphorylation of paxillin on serines 83/126/130 is still needed for both EGFR and PKC-mediated cellular proliferation. Thus, paxillin serves as a specific upstream regulator of Erk in response to receptor-tyrosine kinase signaling but as a general regulator of downstream Erk actions regardless of agonist. Importantly, Erk-mediated serine phosphorylation of paxillin is also required for DHT-induced prostate-specific antigen mRNA expression in LnCAP cells as well as EGF-induced cyclin D1 mRNA expression in PC3 cells, suggesting that paxillin may regulate prostate cancer proliferation by serving as a liaison between extra-nuclear kinase signaling and intra-nuclear transcriptional signals. Thus, paxillin may prove to be a novel diagnostic or therapeutic target in prostate cancer.
Arnold,
Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
2005, Pubmed
Arnold,
Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
2005,
Pubmed
Askari,
The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through beta-adrenergic transactivation of EGF receptors.
2005,
Pubmed
Brown,
Paxillin: adapting to change.
2004,
Pubmed
Cai,
Glycogen synthase kinase 3- and extracellular signal-regulated kinase-dependent phosphorylation of paxillin regulates cytoskeletal rearrangement.
2006,
Pubmed
Campos,
Beta1 integrins activate a MAPK signalling pathway in neural stem cells that contributes to their maintenance.
2004,
Pubmed
Carey,
Ras-MEK-ERK signaling cascade regulates androgen receptor element-inducible gene transcription and DNA synthesis in prostate cancer cells.
2007,
Pubmed
Chen,
Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin.
2004,
Pubmed
Cheng,
Testosterone activates mitogen-activated protein kinase via Src kinase and the epidermal growth factor receptor in sertoli cells.
2007,
Pubmed
Cinar,
Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains.
2007,
Pubmed
Deakin,
Paxillin comes of age.
2008,
Pubmed
Dimri,
Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior.
2007,
Pubmed
Dobkin-Bekman,
A preformed signaling complex mediates GnRH-activated ERK phosphorylation of paxillin and FAK at focal adhesions in L beta T2 gonadotrope cells.
2009,
Pubmed
Evaul,
Cross-talk between G protein-coupled and epidermal growth factor receptors regulates gonadotropin-mediated steroidogenesis in Leydig cells.
2008,
Pubmed
Festuccia,
Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro.
2009,
Pubmed
Filardo,
Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.
2002,
Pubmed
Fix,
Testosterone activates mitogen-activated protein kinase and the cAMP response element binding protein transcription factor in Sertoli cells.
2004,
Pubmed
Frame,
Newest findings on the oldest oncogene; how activated src does it.
2004,
Pubmed
Franco,
Mitogen-activated protein kinase pathway is involved in androgen-independent PSA gene expression in LNCaP cells.
2003,
Pubmed
Fu,
Hormonal control of androgen receptor function through SIRT1.
2006,
Pubmed
Gamble,
Androgens target prohibitin to regulate proliferation of prostate cancer cells.
2004,
Pubmed
Goi,
An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity.
2000,
Pubmed
Hagel,
The adaptor protein paxillin is essential for normal development in the mouse and is a critical transducer of fibronectin signaling.
2002,
Pubmed
Hammes,
Extranuclear steroid receptors: nature and actions.
2007,
Pubmed
Ishibe,
Phosphorylation-dependent paxillin-ERK association mediates hepatocyte growth factor-stimulated epithelial morphogenesis.
2003,
Pubmed
Ishibe,
Paxillin serves as an ERK-regulated scaffold for coordinating FAK and Rac activation in epithelial morphogenesis.
2004,
Pubmed
Jamnongjit,
Epidermal growth factor receptor signaling is required for normal ovarian steroidogenesis and oocyte maturation.
2005,
Pubmed
Kasai,
The Group 3 LIM domain protein paxillin potentiates androgen receptor transactivation in prostate cancer cell lines.
2003,
Pubmed
Ku,
Phosphorylation of paxillin via the ERK mitogen-activated protein kinase cascade in EL4 thymoma cells.
2000,
Pubmed
Lange,
Integration of rapid signaling events with steroid hormone receptor action in breast and prostate cancer.
2007,
Pubmed
Leevers,
Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane.
1994,
Pubmed
Li,
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.
2007,
Pubmed
Lidke,
ERK nuclear translocation is dimerization-independent but controlled by the rate of phosphorylation.
2010,
Pubmed
Lu,
The spatiotemporal pattern of Src activation at lipid rafts revealed by diffusion-corrected FRET imaging.
2008,
Pubmed
Mansour,
Transformation of mammalian cells by constitutively active MAP kinase kinase.
1994,
Pubmed
Mao,
Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential.
1997,
Pubmed
Migliaccio,
Crosstalk between EGFR and extranuclear steroid receptors.
2006,
Pubmed
Migliaccio,
Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation.
2000,
Pubmed
Nishiyama,
The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
2007,
Pubmed
O'Malley,
Nuclear receptor coregulators in cancer biology.
2009,
Pubmed
Peterziel,
Rapid signalling by androgen receptor in prostate cancer cells.
1999,
Pubmed
Qi,
MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
2009,
Pubmed
Rasar,
Paxillin regulates steroid-triggered meiotic resumption in oocytes by enhancing an all-or-none positive feedback kinase loop.
2006,
Pubmed
,
Xenbase
Razandi,
Proximal events in signaling by plasma membrane estrogen receptors.
2003,
Pubmed
Ripple,
Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells.
1997,
Pubmed
Robinson,
Contributions of the mitogen-activated protein (MAP) kinase backbone and phosphorylation loop to MEK specificity.
1996,
Pubmed
Sastry,
Epidermal growth factor protects prostate cancer cells from apoptosis by inducing BAD phosphorylation via redundant signaling pathways.
2006,
Pubmed
Seong,
Visualization of Src activity at different compartments of the plasma membrane by FRET imaging.
2009,
Pubmed
Suzuki,
Androgen receptor involvement in the progression of prostate cancer.
2003,
Pubmed
Titus,
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
2005,
Pubmed
Tremblay,
Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma.
1996,
Pubmed
Unni,
Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
2004,
Pubmed
Varricchio,
Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor alpha tyrosine-phosphorylated peptide.
2007,
Pubmed
Wade,
Paxillin null embryonic stem cells are impaired in cell spreading and tyrosine phosphorylation of focal adhesion kinase.
2002,
Pubmed
Walker,
FSH and testosterone signaling in Sertoli cells.
2005,
Pubmed
Webb,
Paxillin phosphorylation sites mapped by mass spectrometry.
2005,
Pubmed
Woodrow,
Ras-induced serine phosphorylation of the focal adhesion protein paxillin is mediated by the Raf-->MEK-->ERK pathway.
2003,
Pubmed
Xu,
Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family.
2009,
Pubmed
Xu,
Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.
2006,
Pubmed
Zhang,
Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment.
2009,
Pubmed
Zheng,
SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells.
2006,
Pubmed
Zhu,
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.
2008,
Pubmed
